Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance
Marco Ladetto1, Rita Tavarozzi1, Christiane Pott2
1Struttura Complessa di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, via Venezia 16, Alessandria 15121, Italy.
Abstract:
Several biological and clinical features have been recognized in mantle cell lymphoma (MCL). In recent years, the minimal residual disease (MRD) has been extensively investigated and is now considered as one of the strongest clinical predictors in this lymphoma. This article reviews methods used for the assessment of MRD in MCL and discusses their strengths and weaknesses. In addition, it examines the MRD contribution to the biology knowledge of MCL and the development of effective strategies for its management, including the possibility of personalized treatment based on MRD response.
